Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00395759 · ClinicalTrials.gov registry record · NA

The Visual Effect of an Investigational Artificial Tear in the Tear Layer.

A NA study of Dry Eye Disease, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT00395759 is a NA study of Dry Eye Disease that has completed, run by Southern California College of Optometry at Marshall B. Ketchum University. The registered enrollment target is 30 participants, below the 254-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00395759, a NA study of Dry Eye Disease, has completed, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate how the addition of a new artificial tear product when applied to the tear layer affects contrast sensitivity and optical aberrations over time. We will also determine if there are any adverse effects associated with drop instillation.

Conditions Studied

Interventions

  • DRUG Optiva artificial tear by Allergan

Study Locations (1)

California

  • Southern California College of Optometry - Fullerton

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2005-09
Est. Completion 2007-09
Phase NA

What the Registry Record Tells You About NCT00395759

The ClinicalTrials.gov registry entry for NCT00395759 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (88% lower). The listed sponsor is Southern California College of Optometry at Marshall B. Ketchum University, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 1 intervention - of which Optiva artificial tear by Allergan is the first listed.

NCT00395759 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00395759 about?

NCT00395759 is a clinical study titled "The Visual Effect of an Investigational Artificial Tear in the Tear Layer.". The purpose of this study is to investigate how the addition of a new artificial tear product when applied to the tear layer affects contrast sensitivity and optical aberrations over time. We will also determine if there are any adverse effects associated with drop instillation.

What is the current status of trial NCT00395759?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2005-09. Estimated completion is 2007-09.

What conditions does trial NCT00395759 study?

This clinical trial studies the following conditions: Dry Eye Disease.

What interventions are being tested in trial NCT00395759?

The interventions under investigation include: Optiva artificial tear by Allergan (DRUG).

Who is sponsoring clinical trial NCT00395759?

This trial is sponsored by Southern California College of Optometry at Marshall B. Ketchum University, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00395759 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.